DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Study to Evaluate the Safety and Bioequivalence of Mupirocin Calcium Cream, 2% and Bactroban� Cream and Compare Both to a Vehicle in Treatment of Secondarily Infected Traumatic Skin Lesions.

Information source: Taro Pharmaceuticals USA
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Secondarily Infected Traumatic Skin Lesions

Intervention: Mupirocin Calcium Cream, 2% (Drug); Bactroban® Cream (Drug); Cream vehicle of test product (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Taro Pharmaceuticals USA

Summary

The primary objective of this study is to determine the comparability of the safety and efficacy of Mupirocin Calcium Cream, 2% and Bactroban Cream in subjects with secondarily infected traumatic skin lesions. It will also be determined whether the efficacy of each of the active treatments is superior to that of the vehicle cream (placebo).

Clinical Details

Official title: A Double-Blind, Randomized, Parallel-Group, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Bioequivalence of a Generic Mupirocin Calcium Cream, 2% and Reference Listed Bactroban Cream (Mupirocin Calcium Cream, 2%) and Compare Both Active Treatments to a Vehicle Control in the Treatment of Secondarily Infected Traumatic Skin Lesions.

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome: Clinical cure at visit 4

Secondary outcome:

Clinical cure at visit 3

Bacteriological cure at visit 3

Bacteriological cure at visit 4

Eligibility

Minimum age: 18 Months. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Healthy male or nonpregnant females aged 18 months or older with a secondarily

infected traumatic skin lesion such as a laceration, sutured wound, or abrasion.

- The laceration or sutured wound should not exceed 10 cm in length with surrounding

erythema not more than 2 cm from the edge of the lesion. An abrasion should not exceed 100 cm2 in total area with surrounding erythema not more than 2 cm from the edge of the abrasion.

- Positive baseline culture for S. aureus and/or S. pyogenes from a sample taken from

the secondarily infected traumatic skin lesion.

- Positive Gram stain or Wright stain for confirmation of white blood cells in the

pus/exudate from the secondarily infected traumatic skin lesion.

- Skin Infection Rating Scale total score for the secondarily infected traumatic skin

lesion of at least 8 at baseline.

- Women of childbearing potential, in addition to having a negative urine pregnancy

test, must be willing to use an acceptable form of birth control during the study. Subjects entering the study who are on hormonal contraceptives must have been on the method for at least 90 days prior to the study and continue the method for the duration of the study. Subjects who had used hormonal contraception and stopped must have stopped no less than 90 days prior to the study.

- Subjects 18 years of age or older must provide Institutional Review Board approved

written informed consent. Subjects under the age of 18 years must have parent or legal guardian provide Institutional Review Board approved written consent. An assent form for minors must be completed for subjects under the legal age of consent, depending on the age range required by state laws.

- Subjects must be willing and able to understand and comply with the requirements of

the study, apply the medication as instructed, return for the required study visits, comply with therapy prohibitions, and be able to complete the study.

- Subjects must be in good health and free from any clinically significant disease,

other than secondarily infected traumatic skin lesions, that might interfere with the study evaluations. Exclusion Criteria:

- Subjects who are pregnant, nursing, or planning a pregnancy within the study

participation period.

- Any dermatological disorder that may interfere with evaluation of the subject's

secondarily infected traumatic skin lesion(s).

- Bacterial skin infection that, because of depth or severity, could not be

appropriately treated with a topical antibiotic.

- Secondarily infected bite or puncture wound.

- Systemic signs or symptoms of infection.

- Requirement for surgical intervention for treatment of the infection prior to study

entry.

- A subject must not have received any topical corticosteroid, topical antibiotic, or

antifungal agent for at least 48 hours (2 days) prior to baseline.

- A subject must not have received any systemic antibiotic or systemic corticosteroid

for at least 7 days prior to baseline.

- Primary or secondary immunodeficiency.

- Diabetes.

- Presence of any other medical condition that might adversely affect the safety of the

study participants or confound the study results.

- History of hypersensitivity or allergy to mupirocin and/or any of the study

medication ingredients.

- Subjects who consume excessive amounts of alcohol, abuse drugs, or have any condition

that would compromise compliance with the protocol.

- Treatment with an investigational drug or device within 30 days prior to study entry.

- Previously enrollment in this study.

Locations and Contacts

Additional Information

Starting date: February 2013
Last updated: June 9, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017